Key facts
- This page summarizes Leen Kawas's Form 4 filing for Eiger BioPharmaceuticals, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2023, 21:14.
Leen Kawas - 31 Oct 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 31 Oct 2023
- Net transaction value
- +$6,375
- SEC form
- 4
- Accepted by SEC
- 02 Nov 2023, 21:14:42 UTC
- Prior SEC filing
- 30 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leen Kawas
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Leen Kawas filed Form 4 for Eiger BioPharmaceuticals, Inc. on 02 Nov 2023.
Change
- Previous filing in this sequence was filed on 30 Oct 2023.
- Current net transaction value: +$6,375.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EIGR
transaction
Common Stock
Purchase
- Transaction value
- $3,147
- Shares
- +11,987
- Change %
- +0.27%
- Price
- $0.2625
- Shares after
- 4,379,087
- Date
- 31 Oct 2023
- Ownership
- See footnote.
- Footnotes
- F1, F2
EIGR
transaction
Common Stock
Purchase
- Transaction value
- $3,228
- Shares
- +12,345
- Change %
- +0.28%
- Price
- $0.2615
- Shares after
- 4,391,432
- Date
- 31 Oct 2023
- Ownership
- See footnote.
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds acquired the referenced shares of Common Stock.
Footnote F2
Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest.